玻璃体内注射雷珠单抗联合视网膜光凝治疗糖尿病性黄斑水肿的临床疗效及安全性评价

doi:10.13481/j.1671-587x.20150339

Abstract

Abstract:

Objective To discuss the efficacy and safety of intravitreal injection of ranibizumab combined with laser photocoagulation in the treatment of diabetic macular edema (DME), and to explain the advantages of this combination treatment method in treating DME. Methods 71 patients (85 eyes) with macular edema due to diabetic retinopathy(DR) were randomly divided into combination treatment group (42 eyes received intravitreal injections of ranibizumab combined with laser photocoagulation treatment) and photocoagulation group (43 eyes received laser photocoagulation treatment only).The changes of the best corrected visual acuity (BCVA), the fovea centralis thickness (CMT), and the intraocular pressure before and after treatment were observed and analyzed. Results The BCVA of the patients in combination treatment group was improved after treatment than before (P<0.05), but there was no difference of BCVA in photocoagulation group before and after treatment(P>0.05).The BCVA improvement in combination treatment group was statistically more significant (P<0.05) compared with photocoagulation group in 1 month, 3 months and 6 months after laser photocoagulation treatment.Compared with before treatment, the CMT of the patients in two groups in 1 month, 3 months, 6 months after laser photocoagulation treatment were reduced.At each stage, the CMT of the patients in combination treatment group were lower than those in photocoagulation group (P<0.05).No complications of glaucoma, cataract, vitreous hemorrhage, retinal detachment, choroidal detachment, endophthalmitis and no systemic complications were observed in all patients. Conclusion For the patients with DME, the combination treatment with intravitreal injection of ranibizumab and laser photocoagulation has a more quickly and better therapeutic effect than the sole laser photocoagulation treatment in reducing the macular edema and improving the BCVA, also has less complication.

Key words: ranibizumab, diabetic retinopathy, macular edema, panretinal photocoagulation, macular laser grid

CLC Number:

R774.5

LI Shuyan, LIU Shasha, LIU Lihua, LI Jing. Evaluation on efficacy and safety of combination treatment with intravitreal injection of ranibizumab and laser photocoagulation for diabetic macular edema[J].Journal of Jilin University Medicine Edition, 2015, 41(03): 643-647.

References

[1] Yau JW, Rogers SL, Kawasaki R, et al.Global prevalence and major risk factors of diabetic retinopathy[J].Diabetes Care, 2012, 35(3):556-564.

[2] Paulus YM, Gariano RF.Diabetic retinopathy:a growing concern in an aging population[J].Geriatrics, 2009, 64(2):16-20.

[3] Cantrill HL.The diabetic retinopathy study and the early treatment diabetic retinopathy study[J].Int Ophthalmol Clin, 1984, 24(4):13-29.

[4] Perente I, Alkin Z, Ozkaya A, et al.Focal laser photocoagulation in non-center involved diabetic macular edema [J].Med Hypothesis Discov Innov Ophthalmol, 2014, 3(1):9-16.

[5] Nicholson BP, Schachat AP.A review of clinical trials of anti-VEGF agents for diabetic retinopathy[J].Graefe's Arch Clin Exp Ophthalmol, 2010, 248(7):915-930.

[6] Stewart MW.Critical appraisal of ranibizumab in the treatment of diabetic macular edema[J].Clin Ophthalmol, 2013, 7:1257-1267.

[7] Do DV, Nguyen QD, Khwaja AA, et al.Ranibizumab for edema of the macula in diabetes study:3-year outcomes and the need for prolonged frequent treatment[J].JAMA Ophthalmol, 2013, 131(2):139-145.

[8] Mitchell P, Bandello F, Schmidt-Erfurth U, et al.The RESTORE study:ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema [J].Ophthalmology, 2011, 118(4):615-625.

[9] 葛坚.眼科学[M].2版.北京:人民卫生出版社, 2013:305-307.

[10] Klein R, Moss SE, Meuer SM, et al.The 15-year cumulative incidence of retinal vein occlusion:the Beaver Dam Eye Study[J].Arch Ophthalmol, 2008, 126(4):513-518.

[11] Hua W, Cao S, Cui J, et al.Analysis of reasons for noncompliance with laser treatment in patients of diabetic retinopathy[J].Can J Ophthalmol, 2013, 48(2):88-92.

[12] Massin P, Bandello F, Garweg JG, et al.Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study):a 12-month, randomized, controlled, double-masked, multicenter phase Ⅱ study[J].Diabetes Care, 2010, 33(11):2399-2405.

[13] Nguyen QD, Brown DM, Marcus DM, et al.Ranibizumab for diabetic macular edema:results from 2 phase Ⅲ randomized trials:RISE and RIDE [J].Ophthalmology, 2012, 119(4):789-801.

[14] Rajendram R, Fraser-Bell S, Kaines A, et al.A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema:24-month data:report 3[J].Arch Ophthalmol, 2012, 130(8):972-979.

[15] Evoy KE, Abel SR.Ranibizumab:the first vascular endothelial growth factor inhibitor approved for the treatmentof diabetic macular edema[J].Ann Pharmaeother, 2013, 47(6):811-818.

[16] Titchenell PM, Antonetti DA.Using the past to informthe future:anti-VEGF therapy as a road map to developnovel therapies for diabetic retinopathy[J].Diabetes, 2013, 62(6):1808-1815.

[17] 郑志.糖尿病视网膜病变临床防治:进展、挑战与展望[J].中华眼底病杂志, 2012, 28(3), 209-214.

[18] Brown DM, Nguyen QD, Marcus DM, et al.Long-term outcomes of ranibizumab therapy for diabetic macular edema:the 36-month results from two phase Ⅲ trials RISE and RIDE[J].Ophthalmology, 2013, 120(10):2013-2022.

Evaluation on efficacy and safety of combination treatment with intravitreal injection of ranibizumab and laser photocoagulation for diabetic macular edema

PDF (PC)

Like

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 8

Metrics

Comments

Recommended 0

[1]	YANG Jie, MA Yinghui, CUI Xiucheng, WANG Hongmei, DONG Weili, TAN Xiaobo. Expression of MMP-2 in retina tissue of diabetic retinopathy model rats [J]. Journal of Jilin University Medicine Edition, 2017, 43(05): 923-927.
[2]	YANG Jie, MA Yinghui, CUI Xiucheng, WANG Hongmei, DONG Weili, TAN Xiaobo. Hypoglycemic effect of panaxnotoginseng polysaccharides in diabetic model ratsand its therapeutic effect on diabetic retinopathy and their mechanisms [J]. Journal of Jilin University Medicine Edition, 2017, 43(04): 734-738.
[3]	LI Shu-yan,MIAO Lin,CHEN Han,LIU Sha-sha. Efficacy and safety of combination treatment with triamcinolone  acetonide retrobulbar injection and panretinal  photocoagulation in diabetic macular edema [J]. Journal of Jilin University Medicine Edition, 2014, 40(06): 1289-1292.
[4]	. Effect of somatostatin on early electroretinogram in diabetic rats [J]. Journal of Jilin University Medicine Edition, 2014, 40(06): 1192-1196.
[5]	TIAN Kuo, NI Jin-song, WANG Xin-rui， CHEN Di， WU Jia-xiang， ZHAO Xue-jian， YANG Bao-xue. Effect of high concentration glucose on AQP4 expression in rabbit retina Müller cell cultured in vitro [J]. J4, 2007, 33(5): 871-874.
[6]	LENG Ying，MA Jia，WANG Yue-hui，LIU Xiang-long，ZHANG Xiao-guang. Expression and position fixing of bFGFin retina of diabetic rabbits [J]. J4, 2006, 32(4): 600-602.
[7]	NI Jin-song,WANG Yue-hui, CHEN Lan-yue,SHI Bo, WANG Xin-rui, WU Jia-xiang. Protective effects of Ginkgo biloba L. on bovine retinal pericytes [J]. J4, 2005, 31(3): 368-371.
[8]	YANG Wei, SONG E, LIU Ke-hui. Relations of AGEs and dyslipidemia with diabetic retinopathy [J]. J4, 2005, 31(1): 104-107.